Loading stock data…
Phathom Pharmaceuticals, Inc. (PHAT)
$9.43-0.07 (-0.74%)
Market ClosedLast close Sep 8
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phathom Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.43 with a market capitalization of $775M. Wall Street consensus targets $21.50 (10 analysts), implying a +128.0% move over the next 12 months. The stock is currently near its 52-week low of $8.21, remaining 21.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +128.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $74.27M↑ | $58.30M↑ | $57.58M↑ | $49.50M↑ | $39.50M |
| Gross Profit | $59.18M↑ | $46.30M↓ | $49.94M↑ | $43.31M↑ | $34.47M |
| Operating Income | -$3.96M↑ | -$15.48M↓ | -$5.93M↑ | -$15.27M↑ | -$59.92M |
| Net Income | -$17.58M↑ | -$30.37M↓ | -$21.15M↑ | -$29.97M↑ | -$75.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$775.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.78%
Volume
Today's trading volume
1.03M
Recent News
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts
The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a more cautious tone in recent research, where Q2 results, revised 2026 revenue guidance, and fresh views on Voquezna's commercial path are all feeding into how targets are being set. As you read on, you will see what is driving the evolving narrative and how to keep track of the key signals. Stay...
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.
Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan. The company report
Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ...
Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?